Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Ho-jin D. Shin

Busan, KR 
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Busan, KR 
OverviewLocationsClinical Research

Overview

Ho-jin Shin practices in Busan, Republic of Korea. Shin is rated as an Experienced expert by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Agranulocytosis, B-Cell Lymphoma, Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 162 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Locations

Busan, Republic of Korea
Other Locations
Gudeok, Republic of Korea
Ansan, Republic of Korea
Seoul, Republic of Korea
Incheon, Republic of Korea
Daejeon, Republic of Korea
Yangsan, Republic of Korea
Puch'on, 420743, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3

162 Total Publications

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shin's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile